Philadelphia Trust Company’s Alexion Pharmaceuticals ALXN Stock Holding History

Philadelphia Trust Company’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,600	Closed	-$661K	–	250
2021 Q2	$661K	Sell	3,600 -50	-1%	-$8.58K	0.05%	161
2021 Q1	$558K	Sell	3,650 -150	-4%	-$23.2K	0.04%	163
2020 Q4	$594K	Buy	3,800 +300	+9%	+$38.5K	0.05%	143
2020 Q3	$401K	Hold	3,500	–	–	0.04%	154
2020 Q2	$393K	Hold	3,500	–	–	0.04%	138
2020 Q1	$314K	Hold	3,500	–	–	0.04%	136
2019 Q4	$379K	Hold	3,500	–	–	0.03%	169
2019 Q3	$343K	Hold	3,500	–	–	0.03%	175
2019 Q2	$458K	Hold	3,500	–	–	0.04%	165
2019 Q1	$473K	Hold	3,500	–	–	0.04%	163
2018 Q4	$341K	Hold	3,500	–	–	0.04%	148
2018 Q3	$487K	Hold	3,500	–	–	0.04%	151
2018 Q2	$435K	Hold	3,500	–	–	0.04%	156
2018 Q1	$390K	Hold	3,500	–	–	0.03%	165
2017 Q4	$419K	Hold	3,500	–	–	0.03%	171
2017 Q3	$491K	Hold	3,500	–	–	0.04%	158
2017 Q2	$426K	Hold	3,500	–	–	0.04%	160
2017 Q1	$424K	Hold	3,500	–	–	0.03%	164
2016 Q4	$428K	Hold	3,500	–	–	0.03%	163
2016 Q3	$429K	Hold	3,500	–	–	0.04%	160
2016 Q2	$409K	Hold	3,500	–	–	0.04%	153
2016 Q1	$488K	Hold	3,500	–	–	0.04%	132
2015 Q4	$625K	Hold	3,500	–	–	0.05%	122
2015 Q3	$547K	Buy	3,500 +2,867	+453%	+$523K	0.05%	119
2015 Q2	$3.5K	Sell	633 -3,367	-84%	-$581K	0.01%	170
2015 Q1	$693K	Hold	4,000	–	–	0.05%	126
2014 Q4	$740K	Hold	4,000	–	–	0.06%	110
2014 Q3	$663K	Hold	4,000	–	–	0.04%	121
2014 Q2	$625K	Hold	4,000	–	–	0.04%	116
2014 Q1	$609K	Hold	4,000	–	–	0.04%	126
2013 Q4	$532K	Hold	4,000	–	–	0.03%	140
2013 Q3	$465K	Hold	4,000	–	–	0.03%	135
2013 Q2	$369K	Buy	+4,000	New	+$385K	0.03%	137

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Philadelphia Trust Company's ALXN Position: Q3 2021 in Review

Philadelphia Trust Company sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,600 shares — an estimated $661K sold.

Philadelphia Trust Company first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $740K in Q4 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Philadelphia Trust Company reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Philadelphia Trust Company sold 3,600 Alexion Pharmaceuticals shares in Q3 2021, an estimated $661K.
Philadelphia Trust Company first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
Philadelphia Trust Company's Alexion Pharmaceuticals position peaked at $740K in Q4 2014.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Philadelphia Trust Company's 13F filing for Q3 2021, filed 15 Nov 2021.